Affirmed Therapeutics (AFMD) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Shares of Affimed Inc. AFMD were up a massive 246.8% post announcement of a cancer collaboration agreement with Roche Holding’s RHHBY subsidiary, Genentech, on Monday Aug 27. In fact, the stock has ...
Leadership from AMCOM's Aviation Field Maintenance Directorate and Field Support Directorate traveled to Fort Bragg, N.C., in late June to meet with the 82nd Combat Aviation Brigade command team and ...
A legitimate question of whether the company would conduct a necessary follow-on offering (or PIPE these days) on this data is out there. The fact that AFMD has not done so yet is a good sign in my ...
Short interest in AFMD (AFMD) increased during the last reporting period, rising from 580.55K to 928.60K. This put -% of the company's publicly available shares short. Short interest in Corp ...
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients’ money after undertaking a rigorous examination of any potential stock. They are particularly ...
The big shareholder groups in Affimed N.V. (NASDAQ:AFMD) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable ...
The successful funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research ...
Shares of Affimed Inc.AFMD were up a massive 246.8% post announcement of a cancer collaboration agreement with Roche Holding's RHHBY subsidiary, Genentech, on Monday Aug 27. In fact, the stock has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback